WO1993023023A1 - Method for preventing endothelium damage in mammals and for alleviating pain associated with gout and arthritis - Google Patents
Method for preventing endothelium damage in mammals and for alleviating pain associated with gout and arthritis Download PDFInfo
- Publication number
- WO1993023023A1 WO1993023023A1 PCT/CA1993/000198 CA9300198W WO9323023A1 WO 1993023023 A1 WO1993023023 A1 WO 1993023023A1 CA 9300198 W CA9300198 W CA 9300198W WO 9323023 A1 WO9323023 A1 WO 9323023A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ssao
- methylamine
- mammals
- gout
- arthritis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
Definitions
- a method for preventing endothelium damage in mammals comprises administering to a patient in need thereof an effective amount of a SSAO inhibitor for the purpose of preventing endothelium damage in mammals.
- a method for the treatment of cardiovascular disorders associated with diabetes and uraemia in mammals comprises administering to a patient in need thereof an effective amount of a SSAO inhibitor for the purpose of treating cardiovascular disorders associated to diabetes and uraemia.
- the invention also relates to a method for alleviating pain associated with gout and arthritis in mammals.
- the method comprises administering to a patient in need thereof an effective amount of a SSAO inhibitor for the purpose of alleviating pain associated with gout and arthritis in mammals.
- Preferred SSAO inhibitors include (E)-2-(4- fluorophenethyl)-3-fluoroallylamine HC1 (MDL-72974A) and derivatives of fluoroallyla ine, semicarbazide and other hydrazide.
- MDL-72974A 2-(4- fluorophenethyl)-3-fluoroallylamine HC1
- Compounds such as those described in yles et al. (1987 Biochem. Pharmacol. 36:2847 and in U.S. Patent 4,650,907 issued March 7, 1987, U.S. Patent 4,916,151 issued April 10, 1990, U.S. Patent 4,943,593 issued July 24, 1990, U.S.
- SSAO inhibitors for preventing endothelium damage in mammals.
- a preferred embodiment of the invention includes the use of the SSAO inhibitor in the treatment of cardiovascular disorders associated with diabetes and uraemia in mammals.
- SSAO inhibitors for alleviating pain associated with gout and arthritis in mammals.
- Preferred SSAO inhibitors include those referred to above.
- a SSAO inhibitor in the preparation of a medicament for preventing endothelium damage in mammals.
- a preferred embodiment of the present invention includes the use of a SSAO inhibitor for the preparation of a medicament for the treatment of cardiovascular disorders associated with diabetes and uraemia in mammals.
- the invention also relates to the use of a SSAO inhibitor in the preparation of a medicament for alleviating pain associated with gout and arthritis in mammals.
- Preferred SSAO inhibitors include those referred to above.
- the present invention also relates to a method for the in vivo inhibition of SSAO.
- the method comprises administering to a patient in need thereof a SSAO inhibitory substance or a pharmaceutically acceptable salt thereof in sufficient concentration to provide the desired level of SSAO inhibition.
- Preferred SSAO inhibitors include those referred to above.
- the present invention is also concerned with the use of SSAO inhibitors for the in vivo inhibition of SSAO.
- Preferred SSAO inhibitors include those referred to above.
- vascular damage is a major contributing factor to morbidity and mortality in diabetes. Damage to the endothelium thus appears to be a target in diabetes, atherosclerosis and even in hypertension. SSAO inhibitor treatment of patients afflicted with these disorders is therefore a choice therapy to reduce endothelium damage.
- Retinopathy is more prevalent in diabetes than in the normal population (Klein et al, 1989, Arch. Ophthalmol. 107:237). Relatively large amount of SSAO activity has been detected in the rat eye (Cao Danh H, et al,1985, J. Pharm. Pharmacol 37:354). It is possible that bio-conversion of methylamine to formaldehyde may be enhanced in the microvessels, the retina or the smooth muscles of the eye in diabetics. As a result the eye will be damaged and subsequently causes blindness in these patients. Methanol is well known to cause blindness. The mechanism of such damage is also known to be related to the formation of formaldehyde by enzymes. Inhibition of SSAO by appropriate inhibitors can therefore contribute in reducing incidence of retinopathy in diabetes patients. DETAILED DESCRIPTION OF THE INVENTION
- the invention relates to a method for preventing endothelium damage in mammals, particularly the treatment of cardiovascular disorders associated with diabetes and uraemia using SSAO inhibitors.
- the invention also relates to a method for alleviating pain associated with gout and arthritis using SSAO inhibitors.
- SSAO is an enzyme or group of enzymes residing predominantly in the plasma membrane of vascular smooth muscle cells, such as in blood vessels and heart tissues. Although this enzyme has been known for quite some time, its physiological importance had not been well established. Methylamine is deaminated by several semicarbazide-sensi ive a ine oxidases (SSAO) prepared from blood and vascular tissues of several different species including human. While methylamine itself is relatively nontoxic towards endothelial cells obtained from both human vein artery and calf pulmonary veins, it becomes very toxic in the presence of SSAO. It has been found that the endogenous bio-conversion of methylamine to formaldehyde is responsible for certain pathological conditions such as cardiovascular damage. This endogenous bio-conversion can be stopped in mammals by administering suitable amounts of SSAO inhibitors.
- SSAO semicarbazide-sensi ive a ine oxidases
- SSAO inhibitors i.e. MDL-72974A (E)-2-(4- fluorophenethyl)-3-fluoroallylamine HC1) and semicarbazide, effectively protected cells from SSAO-methylamine induced damage.
- Formaldehyde the deaminated product of methylamine, was found to be responsible for toxic effects in cells.
- an abnormal metabolism of methylamine is likely to be involved in endothelial injury by inducing atherosclerotic plaque formation and thus contributing in causing the cardiovascular disorders seen in diabetes.
- Blocking the production of formaldehyde by inhibition of SSAO activity i.e. by SSAO inhibitors, MDL-72974A and semicarbazide
- SSAO inhibitors required to efficiently prevent endothelium damage in mammals, particularly to treat cardiovascular disorders in diabetes and uraemia patients or to alleviate pain associated with gout and arthritis vary depending upon the severity of the ailment.
- the SSAO inhibitors can be administered in various manners to achieve the desired SSAO inhibitory effect.
- the SSAO inhibitors can be administered alone or in combination with pharmaceutically acceptable carriers or diluents, the proportion and nature of which are determined by the solubility and chemical properties of the inhibitor selected, the chosen route of administration, and standard pharmaceutical practice.
- the SSAO inhibitors may be administered orally in solid dosage forms, e.g. capsules, tablets, powders, or in liquid forms, e.g. solutions or suspensions.
- the inhibitors may also be injected parenterally in the form of sterile solutions or suspensions.
- Solid oral forms may contain conventional excipients, for instance: lactose, sucrose, magnesium stearate, resins, and like materials.
- Liquid oral forms may contain various flavoring, coloring, preserving, stabilizing, solubilizing, or suspending agents.
- Parenteral preparations are sterile aqueous or non-aqueous solutions or suspensions which may contain certain various preserving, stabilizing, buffering, solubilizing, or suspending agents.
- additives such as saline or glucose may be added to make the solutions isotonic.
- the amount of SSAO inhibitor administered can vary and can be any effective amount.
- Unit doses of these inhibitors can contain, for example, from about 0.1 g to about 100 g of the inhibitors and may be administered, for example, one or more times daily, as needed.
- unit dosage form is used herein to mean a single or multiple dose form containing a quantity of the active ingredient in admixture with or otherwise in association with the diluent or carrier, said quantity being such that one or more predetermined units are normally required for a single therapeutic administration.
- said predetermined unit is one fraction such as 5 ml (teaspoon) quantity of a liquid or a half or quarter of a scored tablet, of the multiple dose form.
- SSAO was prepared from human umbilical arteries. The dissected tissues were homogenized with a Polytron homogenizer in chilled 0.01 M phosphate buffer (pH 6.8) . These crude homogenates were then centrifuged at 800 g for 10 min and the supernatants centrifuged further at 32,000 g for 30 min. These final supernatant enzyme preparations were either used immediately or stored at -70°C. In the study of SSAO on cell survival the enzyme preparation was thawed and sterilized through a 0.22 ⁇ m filter. SSAO activity was determined by both radioenzymatic and fluorometric methods as previously described (Yu, 1986, In Neuromethod; neutransmitter enzymes.
- CPA 47 endothelial cells (ATCC CRL-1733) derived from the pulmonary vein of normal young calf were grown in Dulbecco's modified Eagle's medium and Ham's nutrient mixture F12 with 15 % fetal bovine serum containing sodium bicarbonate (1.2 g/L) , streptomycin (100 ⁇ g/mL) , penicillin (100 unit/ L) and 1-glutamine (20 mM) and maintained in a humidified atmosphere of 5 % CO, and 95% air at 37°C. Fresh medium was replaced twice a week.
- the vein was perfused with HBSS to wash out blood and followed by infusion of a digestion solution containing 0.2 % collagenase and 0.02 % elastase in HBSS and incubated at 37°C for 20 min.
- the solution containing the endothelial cells were flushed out from the vein and the endothelial cells were collected by centrifugation at 3,000 g for 10 min.
- the pellets were washed once with HBSS and resuspended with Dulbecco's Modified Eagle's Medium (DMEM) containing 20 % fetal bovine serum, penicillin (200 units/mL) streptomycin (200 / ig/mL) and glutamine (20 mM) .
- DMEM Dulbecco's Modified Eagle's Medium
- MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] dye exclusion assay and the estimation of DNA synthesis [i.e. 3H-thymidine incorporation method] was according to Branch and Guibert (1986, J. Tissue Culture Methods 10:101) .
- MTT stock solution was prepared by dissolving 5 mg/mL in PBS which was then filtered to sterilize and remove a small amount of insoluble residue.
- MTT solution was prepared by dilution of the MTT stock with medium of 1% serum.
- Triton-XlOO in PBS
- a cell harvester Brain, Gaithersburg, MD, USA
- BSAO bovine serum amine oxidase
- the substrate preference of the enzymes was assessed by measuring the SSAO activity towards different substrates in comparison to that of benzylamine, a typical SSAO substrate.
- the relative activities of enzymes from the different sources varied considerably.
- Purified BSAO appears to be active towards pentylamine as well as benzylamine, but it is relatively inactive towards methylamine.
- SSAO from bovine aorta seems to exhibit weak activity towards methylamine and tyra ine.
- SSAOs from rat aorta and human umbilical arteries readily deaminate methylamine.
- Methylamine appears to be a better substrate than benzylamine for rat aorta and umbilical artery SSAOs.
- methylamine proved to be toxic towards endothelial cells (CPA 47, ATCC CRL- 1733). Survival of the endothelial cells was assessed using MTT dye exclusion and cell proliferation by thymidine incorporation methods (Table 1) . Methylamine alone did not significantly affect the viability of the cells, except at relatively higher concentrations, i.e. 10 mM, neither did SSAO alone. SSAO in the presence of methylamine, however, caused severe toxic effects on the cultured endothelial cells. The ED50 values were estimated to be 5 xlO -4M and 1x10—5M for the MTT assay and DNA synthesis method respectively. The SSAO inhibitors semicarbazide and MDL-72974A were able to prevent these toxic effects. Semicarbazide is a weak
- SSAO inhibitor so relatively high concentrations (2x10 —4M) were required to prevent partially the death of some of the cells. This is a problem as high concentrations of semicarbazides are difficult to administer in vivo because of their toxicity. MDL-72974A, a much more potent SSAO inhibitor exhibited much better protection against the methylamine-SSAO mediated toxicity and this occurred at much lower
- the cells 24 hours after subculture (6x10 cells/well) on 96-wells plates were used.
- the cultured endothelial cells were incubated with methylamine at different concentrations in the presence or absence of
- SSAO (0.56 nmoles/min/mL).
- MDL-72974A (MDL) (lxl ⁇ "7 M) and semicarbazide (SC) (1x10 -4M) were added 30 mm. before methylamine to inhibit SSAO activity.
- SSAO (0.56 nmoles/min/mL).
- MDL-72974A (MDL) (lxl ⁇ "7 M) and semicarbazide (SC) (lxl0 ⁇ M) were added 30 min. before methylamine to inhibit SSAO activity.
- SSAO inhibitor MDL-72974A also prevented the toxicity of human endothelial cells seen in the presence of SSAO and high concentrations of methylamine. It is worthy of note that the crude SSAO preparations itself, from umbilical veins, exhibited a stimulatory effect on DNA synthesis in both human and bovine endothelial cells. It did not, however, effect the dehydrogenase content as revealed by the MTT method. Morphological effects of methylamine and SSAO on CPA 47 endothelial cells derived from bovine pulmonary vein
- SSAO A small amount of SSAO is known to circulate in normal human blood. Serum obtained from a normal human subject was therefore included in the culture media in order to examine whether or not such serum SSAO is involved in the deamination of methylamine and thus capable of inducing cellular damage. As can be seen in Table 3, methylamine or serum alone does not affect the cell viability. In the presence of both human serum and methylamine, however, the survival of the endothelial cells was reduced. The ED,.- was estimated to be 1x10 -3M. Since human serum 0 SSAO activity is relatively lower than the isolated umbilical SSAO, it is not surprising that it is somewhat less effective in causing damage to the endothelial cells. As was the case with earlier experiments the inclusion of MDL-72974A prevents the appearance of any cytotoxic effects except at high concentration of methylamine. TABLE 3
- this may cause endothelial lesion and subsequently atherosclerosis, or pains at joint tissues, which is rich in SSAO (Lyles and Berti, 1987, Pharmacology Toxicology (supplement), Vol. 60, p. 33) .
- SSAO Stem and Berti, 1987, Pharmacology Toxicology (supplement), Vol. 60, p. 33
- mice Male Swiss white mice (25-30g) were preated with saline or SSAO inhibitor MDL [MDL-72974A, (E)-2-(4-fluorophenethyl)-3-fluoroallylamine] , followed by an i.v. injection of [ C]-methylamine (1 mg/K, 2 ⁇ ci/mouse) .
- Urinary methylamine levels have also been found in STZ-induced diabetic mice. As can be seen in Table 5, the urinary methylamine levels are not significantly increased in the STZ-induced diabetic rats. When the rats were treated with SSAO inhibitor MDL-72974A, urinary methylamine increased significantly. There was an additional increase of urinary methylamine in the diabetic rats treated with MDL-72974A. These results suggest that STZ does induce the synthesis of methylamine. The increase of methylamine was not detectable in the case of treatment with STZ alone, because methylamine would be quickly metabolized by SSAO. If SSAO is blocked, however, the increase of methylamine then becomes apparent.
- Diabetic rats were induced by single i.p. administration of STZ (60 mg/Kg, i.p.).
- STZ 60 mg/Kg, i.p.
- SSAO activity was inhibited by daily i.p. injections of inhibitor MDL-72974A (2 mg/Kg) .
- Methylamine was prepurified through a Sep-Pak of C-18 cartridge, derivatized with OPA and analyzed by HPLC with fluorometric detection. a statistically significant from the saline controls b statistically significant different between the MDL groups.
- Methylamine has been found to be readily deaminated by SSAO to produce formaldehyde. Methylamine has been detected in different mammalian tissues and in blood and is excreted in relatively large quantities by humans. Methylamine can be derived from the diet,, gut bacterial degradation of dietary precursors, and from various metabolic pathways for the degradation of creatinine, sarcosine and adrenaline. Normal circulating and urinary concentrations of methylamine are increased in certain physiological and pathological (i.e. diabetes, uraemia) circumstances. SSAO, which presents predominantly in the vascular and cartilage tissues, exhibits a reasonably high affinity for methylamine with a Km value of 1 x 10-4 M. The urinary excretion of methylamine is increased in rats treated with SSAO inhibitors. Methylamine is therefore an endogenous substrate.
- SSAO Cultured endothelial cells derived from both bovine and human blood vessels possess negligible SSAO activity.
- Calf serum which is used in culture media, contains small amounts of deaminating activity towards benzylamine (probably due to BSAO) ; it exhibits quite low activity towards methylamine, however. This explains why methylamine by itself does not exhibit toxicity towards the endothelial cells as assessed by MTT dye exclusion measurement.
- SSAO isolated from human umbilical arteries is included in the cell culture media, toxicity to methylamine is induced. This toxic effect of deamination of methylamine on endothelial cells is even more pronounced, when DNA synthesis ([ H]-thymidine incorporation study) is assessed.
- DNA synthesis in the endothelial cells was observed to be enhanced by the addition of the umbilical SSAO preparation, which perhaps indicate the presence of some growth factors.
- the methylamine-SSAO mediated cytotoxicity is a result of deamination of methylamine.
- MDL-72974A the SSAO inhibitor MDL-72974A to prevent completely this methylamine-SSAO induced toxicity.
- Semicarbazide the classical SSAO inhibitor, also appears be able to protect endothelial cells against these toxic effects, but it is less effective than MDL-72974A. If the deamination of methylamine is uncontrolled, it might cause cellular damage in the blood vessels. This has been proved to be the case for some vascular disorders such as uraemia and diabetes.
- Formaldehyde is capable of conjugating with proteins and nucleic acids, to modify their chemical structures and thus change or inactivate their functions.
- Hydrogen peroxide a strong oxidative agent, is involved in various oxidative reactions and can itself be transformed into an hydroxyl free radical in the presence of certain metal ions. If detoxification of these products were to be deficient in vivo, they could cause tissue damage. It is interesting to know whether formaldehyde or hydrogen peroxide is responsible for causing the cytotoxicity of the endothelial cells seen in this present study. An approximately 30-fold higher concentration of hydrogen peroxide , however, is required to induce endothelial damage similar to that seen with formaldehyde. This suggests that the toxicity induced by methylamine deamination is due primarily to the production of formaldehyde rather than hydrogen peroxide.
- SSAO-me&iated conversion of methylamine to formaldehyde occurs in the blood or the vascular tissues.
- Vascular disorders could be,therefore, induced where SSAO is located.
- Blood methylamine levels have been estimated to be 2.3 ⁇ g/100 mL (7.4xlO-7M) in healthy control subjects and 26 ⁇ g/100 mL ( 8xlO-6M) in patients with chronic renal failure before hae odialysis (Baba et al, 1984, Clin. Chim. Acta. 136:49).
- the methylamine concentration in such patients is thus quite comparable to the concentrations used in the above experiments to cause damage to endothelial cells.
- Vascular problems are known to be associated with patients exhibiting renal failure and dysfunction.
- SSAO activity is about 0.7 nmoles/min/mL. This is also quite similar to the amount of SSAO (0.56 nmoles/min/mL) added to the above described cultured endothelial cell studies.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93909712A EP0639972A1 (en) | 1992-05-15 | 1993-05-14 | Method for preventing endothelium damage in mammals and for alleviating pain associated with gout and arthritis |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2,068,745 | 1992-05-15 | ||
CA 2068745 CA2068745A1 (en) | 1992-05-15 | 1992-05-15 | Treatment of cardiovascular disease associated with diabetes, uremia, gout and arthritis |
CA2,068,927 | 1992-05-19 | ||
CA 2068927 CA2068927A1 (en) | 1992-05-19 | 1992-05-19 | Treatment of cardiovascular disease associated with diabetes, uremia, gout and arthritis |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993023023A1 true WO1993023023A1 (en) | 1993-11-25 |
Family
ID=25675140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1993/000198 WO1993023023A1 (en) | 1992-05-15 | 1993-05-14 | Method for preventing endothelium damage in mammals and for alleviating pain associated with gout and arthritis |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0639972A1 (en) |
AU (1) | AU4055593A (en) |
WO (1) | WO1993023023A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002002541A2 (en) * | 2000-07-05 | 2002-01-10 | Biotie Therapies Corp. | Inhibitors of copper-containing amine oxidases |
WO2002038153A1 (en) * | 2000-11-09 | 2002-05-16 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives |
JP2006522110A (en) * | 2003-03-31 | 2006-09-28 | スキャンポ アーゲー | Methods for treating hypervascular disease |
US7125901B2 (en) | 2003-01-27 | 2006-10-24 | Astellas Pharma Inc. | Thiazole derivatives |
KR20110022574A (en) | 2008-05-30 | 2011-03-07 | 가부시키가이샤 아루떼꾸 우에노 | Benzene or thiophene derivative and use thereof as vap-1 inhibitor |
WO2011034078A1 (en) | 2009-09-16 | 2011-03-24 | アステラス製薬株式会社 | Glycine compound |
US8119651B2 (en) | 2004-01-30 | 2012-02-21 | Biotie Therapies Corp. | Compositions useful especially for treatment or prevention of metabolic syndrome |
WO2012124696A1 (en) | 2011-03-15 | 2012-09-20 | アステラス製薬株式会社 | Guanidine compound |
US8507690B2 (en) | 2008-01-31 | 2013-08-13 | R-Tech Ueno, Ltd. | Thiazole derivative and use thereof as VAP-1 inhibitor |
WO2014199171A1 (en) | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
WO2015189534A1 (en) | 2014-06-12 | 2015-12-17 | Proximagen Limited | Vap-1 inhibitors for treating muscular dystrophy |
WO2016194390A1 (en) | 2015-06-05 | 2016-12-08 | R-Tech Ueno, Ltd. | Pharmaceutical composition for use in the treatment of cancer |
WO2017098237A1 (en) * | 2015-12-07 | 2017-06-15 | Proximagen Limited | (r)-carbidopa alone or in combination with a steroid for treating pain, inflammation, an inflammatory disease, an immune or autoimmune disease and tumour growth. |
WO2017098236A1 (en) * | 2015-12-07 | 2017-06-15 | Proximagen Limited | Vap-1 inhibitors for treating pain |
CN107530330A (en) * | 2015-04-24 | 2018-01-02 | 普罗克斯马根有限公司 | The treatment of pain |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0295604A1 (en) * | 1987-06-16 | 1988-12-21 | Merrell Dow Pharmaceuticals Inc. | (E)-2-(p-Fluorophenethyl)-3-fluoroallylamine |
-
1993
- 1993-05-14 WO PCT/CA1993/000198 patent/WO1993023023A1/en not_active Application Discontinuation
- 1993-05-14 AU AU40555/93A patent/AU4055593A/en not_active Abandoned
- 1993-05-14 EP EP93909712A patent/EP0639972A1/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0295604A1 (en) * | 1987-06-16 | 1988-12-21 | Merrell Dow Pharmaceuticals Inc. | (E)-2-(p-Fluorophenethyl)-3-fluoroallylamine |
Non-Patent Citations (6)
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002002541A3 (en) * | 2000-07-05 | 2002-04-18 | Biotie Therapies Corp | Inhibitors of copper-containing amine oxidases |
WO2002002090A3 (en) * | 2000-07-05 | 2002-05-16 | Biotie Therapies Corp | Inhibitors of copper-containing amine oxidases |
US6624202B2 (en) | 2000-07-05 | 2003-09-23 | Biotie Therapies Corp. | Inhibitors of copper-containing amine oxidases |
WO2002002541A2 (en) * | 2000-07-05 | 2002-01-10 | Biotie Therapies Corp. | Inhibitors of copper-containing amine oxidases |
WO2002038153A1 (en) * | 2000-11-09 | 2002-05-16 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives |
US7125901B2 (en) | 2003-01-27 | 2006-10-24 | Astellas Pharma Inc. | Thiazole derivatives |
US7442715B2 (en) | 2003-01-27 | 2008-10-28 | Astellas Pharma Inc. | Thiazole derivatives |
JP2006522110A (en) * | 2003-03-31 | 2006-09-28 | スキャンポ アーゲー | Methods for treating hypervascular disease |
JP4758337B2 (en) * | 2003-03-31 | 2011-08-24 | 株式会社アールテック・ウエノ | Methods for treating hypervascular disease |
US8119651B2 (en) | 2004-01-30 | 2012-02-21 | Biotie Therapies Corp. | Compositions useful especially for treatment or prevention of metabolic syndrome |
US8507690B2 (en) | 2008-01-31 | 2013-08-13 | R-Tech Ueno, Ltd. | Thiazole derivative and use thereof as VAP-1 inhibitor |
EP2676955A1 (en) | 2008-01-31 | 2013-12-25 | R-Tech Ueno, Ltd. | Thiazole Derivative and use thereof as VAP-1 Inhibitor |
KR20110022574A (en) | 2008-05-30 | 2011-03-07 | 가부시키가이샤 아루떼꾸 우에노 | Benzene or thiophene derivative and use thereof as vap-1 inhibitor |
US9603833B2 (en) | 2008-05-30 | 2017-03-28 | R-Tech Ueno, Ltd. | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor |
EP2886534A1 (en) | 2008-05-30 | 2015-06-24 | R-Tech Ueno, Ltd. | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor |
US8999989B2 (en) | 2008-05-30 | 2015-04-07 | R-Tech Ueno, Ltd. | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor |
WO2011034078A1 (en) | 2009-09-16 | 2011-03-24 | アステラス製薬株式会社 | Glycine compound |
US8802679B2 (en) | 2009-09-16 | 2014-08-12 | Astellas Pharma Inc. | Glycine compound |
US8716470B2 (en) | 2011-03-15 | 2014-05-06 | Astellas Pharma Inc. | Guanidine compound |
US9556160B2 (en) | 2011-03-15 | 2017-01-31 | Astellas Pharma Inc. | Guanidine compound |
US9051283B2 (en) | 2011-03-15 | 2015-06-09 | Astellas Pharma Inc. | Guanidine compound |
KR20140014153A (en) | 2011-03-15 | 2014-02-05 | 아스테라스 세이야쿠 가부시키가이샤 | Guanidine compound |
EP3002278A1 (en) | 2011-03-15 | 2016-04-06 | Astellas Pharma Inc. | Guanidine compound |
WO2012124696A1 (en) | 2011-03-15 | 2012-09-20 | アステラス製薬株式会社 | Guanidine compound |
WO2014199171A1 (en) | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
WO2015189534A1 (en) | 2014-06-12 | 2015-12-17 | Proximagen Limited | Vap-1 inhibitors for treating muscular dystrophy |
CN107530330A (en) * | 2015-04-24 | 2018-01-02 | 普罗克斯马根有限公司 | The treatment of pain |
WO2016194390A1 (en) | 2015-06-05 | 2016-12-08 | R-Tech Ueno, Ltd. | Pharmaceutical composition for use in the treatment of cancer |
WO2017098237A1 (en) * | 2015-12-07 | 2017-06-15 | Proximagen Limited | (r)-carbidopa alone or in combination with a steroid for treating pain, inflammation, an inflammatory disease, an immune or autoimmune disease and tumour growth. |
WO2017098236A1 (en) * | 2015-12-07 | 2017-06-15 | Proximagen Limited | Vap-1 inhibitors for treating pain |
US20180360786A1 (en) * | 2015-12-07 | 2018-12-20 | Proximagen Group Limited | (r)-carbidopa alone or in combination with a steroid for treating pain, inflammation, an inflammatory disease, an immune or autoimmune disease and tumour growth |
EP3777846A1 (en) | 2015-12-07 | 2021-02-17 | BenevolentAI Cambridge Limited | Vap-1 inhibitors for treating pain |
Also Published As
Publication number | Publication date |
---|---|
EP0639972A1 (en) | 1995-03-01 |
AU4055593A (en) | 1993-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dianzani | Biochemical aspects of fatty liver | |
Yu et al. | Oxidative deamination of methylamine by semicarbazide-sensitive amine oxidase leads to cytotoxic damage in endothelial cells: possible consequences for diabetes | |
Cardinali et al. | Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications | |
WO1993023023A1 (en) | Method for preventing endothelium damage in mammals and for alleviating pain associated with gout and arthritis | |
Schmidt et al. | Role of dopamine in the neurotoxic effects of methamphetamine. | |
Song et al. | Sulforaphane protects against cytokine-and streptozotocin-induced β-cell damage by suppressing the NF-κB pathway | |
US5457130A (en) | Eicosapentaenoic acid used to treat cachexia | |
EP0464084B1 (en) | Use of eicosapentaenoic acid for the treatment of cachexia | |
US5348945A (en) | Method of treatment with hsp70 | |
CN104997803B (en) | Comprising the treatment using magnetic dipole stabilizing solutions or improves disease and enhance the method and composition of performance | |
Scheen et al. | Pharmacological treatment of obesity: present status | |
US5316765A (en) | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies | |
CA2339218C (en) | Methods and compositions for increasing insulin sensitivity | |
WO1994008628A1 (en) | Prevention of acetaminophen overdose toxicity with organosulfur compounds | |
Ekstedt et al. | Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment? | |
Karnovsky | Glycogenolytic Effect of 2-mercapto-ethylamine in Epiphyseal Cartilage | |
Smith | Paraquat toxicity | |
EP2097082A1 (en) | Pharmaceutical composition comprising metadoxine and garlic oil for preventing and treating alcohol-induced fatty liver and steatohepatitis | |
Prada et al. | Some basic aspects of reversible inhibitors of monoamine oxidase‐A | |
Masiello et al. | Protective effect of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase, against streptozotocin-induced diabetes | |
EP0547558B1 (en) | Use of aminoguanidine for the manufacture of a medicament for inhibiting nitric oxide formation | |
Sandler | Monoamine oxidase inhibitor efficacy in depression and the ‘cheese effect’1 | |
Schwartz et al. | The biological significance of dehydroepiandrosterone | |
WO1991015219A1 (en) | Method of treatment with hsp70 | |
Nerone et al. | Effects of Melatonin on Metabolic Abnormalities in HIV Patients Treated with Antiretroviral Drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA CZ FI HU JP KP KR KZ LK MG MN MW NO NZ PL RO RU SD SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1994 335757 Date of ref document: 19941114 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993909712 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1993909712 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993909712 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |